Literature DB >> 18852383

Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study.

Julio A Chirinos1, Robert David, J Alexander Bralley, Humberto Zea-Díaz, Edgar Muñoz-Atahualpa, Fernando Corrales-Medina, Carolina Cuba-Bustinza, Julio Chirinos-Pacheco, Josefina Medina-Lezama.   

Abstract

Endogenous NO synthase inhibitors (end-NOSIs) have been associated with cardiovascular risk factors and atherosclerosis. In addition, end-NOSIs may directly cause hypertension through hemodynamic effects. We aimed to examine the association between end-NOSI asymmetrical dimethylarginine (ADMA) and N-guanidino-monomethyl-arginine (NMMA), subclinical atherosclerosis, and arterial hemodynamics. We studied 922 adults participating in a population-based study (PREVENCION Study) and examined the correlation between end-NOSI/L-arginine and arterial hemodynamics, carotid-femoral pulse wave velocity, and carotid intima-media thickness using linear regression. ADMA, NMMA, and L-arginine were found to be differentially associated with various classic cardiovascular risk factors. ADMA and NMMA (but not L-arginine) were significant predictors of carotid intima-media thickness, even after adjustment for cardiovascular risk factors, C-reactive protein, and renal function. In contrast, ADMA and NMMA did not predict carotid-femoral pulse wave velocity, blood pressure, or hemodynamic abnormalities. Higher L-arginine independently predicted systolic hypertension, higher central pulse pressure, incident wave amplitude, central augmented pressure, and lower total arterial compliance but not systemic vascular resistance or cardiac output. We conclude that ADMA and NMMA are differentially associated with cardiovascular risk factors, but both end-NOSIs are independent predictors of carotid atherosclerosis. In contrast, they are not associated with large artery stiffness, hypertension, or hemodynamic abnormalities. Our findings are consistent with a role for asymmetrical arginine methylation in atherosclerosis but not in large artery stiffening, hypertension, or long-term hemodynamic regulation. L-arginine is independently associated with abnormal pulsatile (but not resistive) arterial hemodynamic indices, which may reflect abnormal L-arginine transport, leading to decreased intracellular bioavailability for NO synthesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852383     DOI: 10.1161/HYPERTENSIONAHA.108.120352

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

Review 1.  Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Yuzo Yano; Taku Tsunoda; Takashi Ikawa; Toshihiro Matsuo; Fumihiro Ochi; Yoshiki Kusunoki; Masaru Tokuda; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Exp Med       Date:  2015-05-20

2.  Nitric oxide synthase, ADMA, SDMA, and nitric oxide activity in the paraventricular nucleus throughout the etiology of renal wrap hypertension.

Authors:  Carrie A Northcott; Scott Billecke; Teresa Craig; Carmen Hinojosa-Laborde; Kaushik P Patel; Alex F Chen; Louis G D'Alecy; Joseph R Haywood
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

3.  Heat-assisted extraction for the determination of methylarginines in serum by CE.

Authors:  Thomas H Linz; Susan M Lunte
Journal:  Electrophoresis       Date:  2013-06       Impact factor: 3.535

4.  Optimization of the separation of NDA-derivatized methylarginines by capillary and microchip electrophoresis.

Authors:  Thomas H Linz; Christa M Snyder; Susan M Lunte
Journal:  J Lab Autom       Date:  2012-02

5.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home; Rainer H Boger
Journal:  Curr Cardiol Rev       Date:  2010-05

6.  Optimal definitions for abdominal obesity and the metabolic syndrome in Andean Hispanics: the PREVENCION study.

Authors:  Josefina Medina-Lezama; Catherine A Pastorius; Humberto Zea-Diaz; Antonio Bernabe-Ortiz; Fernando Corrales-Medina; Oscar Leopoldo Morey-Vargas; Diana Andrea Chirinos; Edgar Muñoz-Atahualpa; Julio Chirinos-Pacheco; Julio Alonso Chirinos
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 17.152

7.  Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort.

Authors:  Renke Maas; Vanessa Xanthakis; Joseph F Polak; Edzard Schwedhelm; Lisa M Sullivan; Ralf Benndorf; Friedrich Schulze; Ramachandran S Vasan; Philip A Wolf; Rainer H Böger; Sudha Seshadri
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

8.  Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study.

Authors:  Aleksandra Pikula; Rainer H Böger; Alexa S Beiser; Renke Maas; Charles DeCarli; Edzard Schwedhelm; Jayandra J Himali; Friedrich Schulze; Rhoda Au; Margaret Kelly-Hayes; Carlos S Kase; Ramachandran S Vasan; Philip A Wolf; Sudha Seshadri
Journal:  Stroke       Date:  2009-07-30       Impact factor: 7.914

9.  Prospective risk factors for increased central augmentation index in men and women.

Authors:  Prithvi Shiva Kumar; Josefina Medina-Lezama; Oscar Morey-Vargas; Payman Zamani; Juan F Bolaños-Salazar; Diana A Chirinos; Philip Haines; Zubair A Khan; Johanna C Coacalla-Guerra; Maria E Davalos-Robles; Gladys R Llerena-Dongo; Mardelangel Zapata-Ponze; Julio A Chirinos
Journal:  Am J Hypertens       Date:  2014-05-28       Impact factor: 2.689

10.  Effect of statin on arginine metabolites in treated HIV-infection.

Authors:  Sahera Dirajlal-Fargo; Vanessa El Kamari; Abdus Sattar; Khurshid Alam; Nicholas Funderburg; Danielle Labbato; Lisa Pirro; Chris T Longenecker; Wai Hong Wilson; Grace A McComsey
Journal:  Atherosclerosis       Date:  2017-09-28       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.